Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | ITK | Q08881 | 2/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 4/20 | 0.45 |
| ▸ | BCR | P11274 | 3/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642021 | 0.93 | ABL1 (0.51) | EGFRSLC2A1BRAFABL1BCR | |
| SCHEMBL1641934 | 0.90 | SLC2A1 (0.56) | EGFRITKSLC2A1BRAFABL1 | |
| SCHEMBL1642212 | 0.87 | EGFR (0.47) | EGFRSLC2A1BRAFABL1BCR | |
| SCHEMBL1641928 | 0.87 | SLC2A1 (0.49) | EGFRITKSLC2A1BRAFABL1 | |
| SCHEMBL1640567 | 0.85 | SLC2A1 (0.49) | EGFRSLC2A1BRAFABL1BCR | |
| SCHEMBL1640749 | 0.85 | ABL1 (0.47) | EGFRITKSLC2A1BRAFABL1 | |
| SCHEMBL1640284 | 0.84 | ABL1 (0.50) | EGFRSLC2A1BRAFABL1BCR | |
| SCHEMBL13816024 | 0.82 | EGFR (0.48) | EGFRSLC2A1BRAFABL1BCR | |
| SCHEMBL12726468 | 0.81 | ABL1 (0.47) | EGFRBRAFABL1BCRPDGFRB | |
| SCHEMBL12726479 | 0.81 | AURKA (0.56) | EGFRBRAFABL1BCRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009076140-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098296-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | EGFR 478/4885ITK 193/4885SLC2A1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.